Modulation of the Cardiac Myocyte Action Potential by the Magnesium-Sensitive TRPM6 and TRPM7-Like Current

Asfree Gwanyanya 1,2, Inga Andriulė 3, Bogdan M. Istrate 1, Farjana Easmin 1, Kanigula Mubagwa 1,4 and Regina Mačianskiene 3,*

1 Department of Cardiovascular Sciences, KU Leuven, 3000 Leuven, Belgium; asfree.gwanyanya@uct.ac.za (A.G.); istratem.bogdan@yahoo.com (B.M.I.); feasmin87@gmail.com (F.E.); kanigula.mubagwa@kuleuven.be (K.M.)
2 Department of Human Biology, University of Cape Town, Cape Town 7925, South Africa
3 Institute of Cardiology, Lithuanian University of Health Sciences, 50103 Kaunas, Lithuania; inga.andriule@lsmuni.lt
4 Department of Basic Sciences, Faculty of Medicine, Université Catholique de Bukavu, Bukavu, Congo
* Correspondence: regina.macianskiene@lsmuni.lt

Abstract: The cardiac Mg²⁺-sensitive, TRPM6, and TRPM7-like channels remain undefined, especially with the uncertainty regarding TRPM6 expression in cardiomyocytes. Additionally, their contribution to the cardiac action potential (AP) profile is unclear. Immunofluorescence assays showed the expression of the TRPM6 and TRPM7 proteins in isolated pig atrial and ventricular cardiomyocytes, of which the expression was modulated by incubation in extracellular divalent cation-free conditions. In patch clamp studies of cells dialyzed with solutions containing zero intracellular Mg²⁺ concentration ([Mg²⁺]i) to activate the Mg²⁺-sensitive channels, raising extracellular [Mg²⁺]o from the 0.9-mM baseline to 7.2 mM prolonged the AP duration (APD). In contrast, no such effect was observed in cells dialyzed with physiological [Mg²⁺]. Under voltage clamp, in cells dialyzed with zero [Mg²⁺]i, depolarizing ramps induced an outward-rectifying current, which was suppressed by raising [Mg²⁺]o, and was absent in cells dialyzed with physiological [Mg²⁺]. In cells dialyzed with physiological [Mg²⁺], raising [Mg²⁺]o decreased the L-type Ca²⁺ current and the total delayed-rectifier current but had no effect on the APD. These results suggest a co-expression of the TRPM6 and TRPM7 proteins in cardiomyocytes, which are therefore the molecular candidates for the native cardiac Mg²⁺-sensitive channels, and also suggest that the cardiac Mg²⁺-sensitive current shortens the APD, with potential implications in arrhythmogenesis.

Keywords: TRPM6; TRPM7; ion channel; action potential; cardiac; magnesium; myocyte

1. Introduction

The cardiac cation channels involved in electrical activity and ion homeostasis include well-known ion-selective channels, as well as ion nonselective channels. Apart from the Na⁺- and K⁺-permeable pacemaker or funny (Iₐ) channels [1], not many nonselective cardiac cation channels have been fully characterized; hence, their molecular identities remain uncertain. During the past two decades, there has been a growing interest in transient receptor potential (TRP) proteins as molecular candidates for native cation nonselective channels, including those found in the heart [2]. TRP channels are a large superfamily of proteins expressed in several tissues where they are involved in diverse signaling processes and in disease [3]. Among the various TRP channels expressed in the cardiovascular system, canonical (e.g., TRPC1 and C3–C7), melastatin (e.g., TRPM4 and M7), vanilloid (e.g., TRPV1 and V2), and polycystin (e.g., TRPP1/2) channels are present in the heart and are implicated in the physiological functions and in cardiac abnormalities such as arrhythmogenesis and heart failure [4,5]. The role of cardiac TRP channels has been explored in fibroblasts and in pacemaker cells (see reference [3]) but much less in cardiomyocytes. The few TRPs
that have been electrophysiologically explored in cardiac myocytes include TRPC1 [6], TRPC3/6/7 [7,8], TRPV4 [9], TRPM4 [10], TRPM7 [11,12], and TRPP1/2 [13]. We have previously characterized cardiac Mg\(^{2+}\)-sensitive channels [14,15] with biophysical properties similar to those of the heterologous TRPM6 and TRPM7 channels, both of which are involved in the homeostasis of Mg\(^{2+}\) and other divalent cations [16–20]. Like the heterologously expressed TRPM6 and TRPM7 channels, the cardiomyocyte TRPM6- and TRPM7-like channels are typically activated by low intracellular Mg\(^{2+}\) concentration ([Mg\(^{2+}\)]\(_i\)) conditions and conduct small inward currents carried by divalent cations and large outward currents carried by monovalent cations. These cardiomyocyte Mg\(^{2+}\)-sensitive channels have been detected in various species, including humans, rats, pigs, guinea pigs, and mice. However, the nature of the proteins underlying the cardiac TRPM6- and TRPM7-like currents and the functional consequences of their cation fluxes have remained unclear.

Whereas TRPM7 protein expression has been systematically detected in cardiac tissues or cells, until recently, information regarding the TRPM6 channel protein expression in the heart has remained scant and has concerned only the right atrium [21]. However, very recent data on human atrial/ventricular cardiomyocytes and tissues has highlighted the co-expression of TRPM6 and TRPM7 in cardiomyocytes from all chamber walls of the human heart [22]. As far as function is concerned, we have previously shown the cardiac Mg\(^{2+}\)-sensitive channels to be permeable to Ca\(^{2+}\) and Mg\(^{2+}\) [15] and proposed that, at the resting membrane potential, the inward flow of divalent cations into cells through the channels could have an effect on the intracellular concentrations of the divalent cations (see reference [23]). On the other hand, the contribution of the TRPM6- and TRPM7-like currents to the cardiomyocyte electrical activity is unknown. The possibility that monovalent cation effluxes through Mg\(^{2+}\)-sensitive channels at positive potentials could contribute to action potentials has not been tested.

Here, we investigated the expression profile of TRPM6 and TRPM7 proteins in pig cardiac myocytes, as well as the role of the Mg\(^{2+}\)-sensitive, TRPM6-, and TRPM7-like currents on the cardiac action potential.

2. Results

2.1. Expression of TRPM6 and TRPM7 in Cardiac Myocytes

To show the presence of TRPM6 and TRPM7 proteins, we used the immunostaining of atrial and ventricular cardiomyocytes, performed after 2 h of cell isolation. Figure 1A–D shows confocal images of pig cardiomyocytes co-stained for the nucleus (blue), for either TRPM7 or TRPM6 protein (green), and for the F-actin-cytoskeleton (red), whereas Figure 1E shows a negative control (cardiomyocyte incubated in conditions similar to those of Figure 1A–D but with no primary antibody added in the incubation medium). All the cardiomyocytes displayed staining with antibodies for TRPM6 and TRPM7. Figure 1F shows the quantification of the immunodetected fluorescence of TRPM7 (left panel) and TRPM6 (right panel) in the four cardiac chamber walls: left atrium (LA), right atrium (RA), left ventricle (LV), and right ventricle (RV). Of note was the multinucleated nature of the cells, as previously noted for pig cardiomyocytes [24].

We found that the measured level of expression of the TRPM6 and TRPM7 proteins was influenced by the cell incubation conditions, such as the presence and absence of extracellular divalent cations. The immunofluorescence level of both channel proteins in the cardiomyocytes from all the cardiac chamber walls was significantly higher following cell incubation in divalent cation-containing (DV) extracellular conditions vs. incubation in divalent cation-free (DVF) conditions (see Table 1). In addition, the expression was also increased when incubating cells for a longer period before cell fixation and exposure to the primary antibodies. Figure 2 shows that the mean fluorescence levels for the immunodetected TRPM6 and TRPM7 were significantly increased in LV cardiomyocytes kept for 12 h in solutions with (Figure 2A,B) or without (Figure 2C,D) divalent cations. TRPM7 increased from 0.087 ± 0.0013 a.u. to 0.133 ± 0.0011 a.u., n = 3–23, p < 0.001 in the
DV solutions and from 0.065 ± 0.0009 a.u. to 0.112 ± 0.0006 a.u., n = 4–25, p < 0.001 in the
DVF solutions. Under the same experimental conditions, the TRPM6 immunofluorescence
increased from 0.029 ± 0.0015 a.u. to 0.050 ± 0.0012 a.u., n = 3–24, p < 0.001 and from
0.020 ± 0.0006 a.u. to 0.040 ± 0.0009 a.u., n = 7–21, p < 0.001 in the DV and DVF solutions,
respectively. Qualitatively similar changes could be detected in the cardiomyocytes from
the other cardiac chamber walls when incubated for 12 h (not illustrated).

Figure 1. Immunofluorescence images suggesting the presence of TRPM6 and TRPM7 proteins in pig
cardiomyocytes from different cardiac chamber walls. (A–D) Immunofluorescence of TRPM7 (left)
and TRPM6 (right) in the left atrium (LA), right atrium (RA), left ventricle (LV), and right ventricle
(RV) cardiomyocytes when using Alexa Fluor 488 for the TRPM7 and TRPM6 proteins (stained in
green), Alexa Fluor 546 for the F-actin cytoskeleton (stained in red), and Hoechst 33342 for the nuclei
(stained in blue). Scale bars indicate 20 µm. (E) Example of a negative control, where the primary
antibody for TRPM6 and/or TRPM7 is not added, but the cardiomyocyte was subjected to Hoechst
33342 and Alexa Fluor 546. Under such conditions, only immunofluorescence of the nuclei (stained
in blue) and F actin cytoskeleton (stained in red) is detected. Note: same cardiomyocyte in the left
and right (merged image) panels. (F) Quantification of the staining intensity of the immunodetected
fluorescence of TRPM7 and TRPM6 in the four cardiac chamber walls: LA, RA, LV, and RV. The mean
data is provided in arbitrary units (a.u.) (see Table 1). A blinded study design (with the origin or
treatment of cells unknown to the investigator) was used for the detection of immunofluorescence
during the various experimental conditions.
Table 1. Immunofluorescence signals of the TRPM7 and TRPM6 proteins in pig hearts.

| Heart Chamber | TRPM7 Signal (a.u.) | TRPM6 Signal (a.u.) |
|---------------|---------------------|---------------------|
|               | DV                  | DVF                 | DV                  | DVF                 |
| LA            | 0.067 ± 0.0006      | 0.053 ± 0.0009 #    | 0.023 ± 0.0013      | 0.016 ± 0.0014 #    |
| n = 37        | n = 13              | n = 18              | n = 20              |
| RA            | 0.079 ± 0.0009      | 0.059 ± 0.0010 #    | 0.029 ± 0.0008      | 0.018 ± 0.0011 #    |
| n = 21        | n = 5               | n = 32              | n = 4               |
| LV            | 0.087 ± 0.0013      | 0.065 ± 0.0009 #    | 0.029 ± 0.0015      | 0.020 ± 0.0006 #    |
| n = 23        | n = 25              | n = 24              | n = 21              |
| RV            | 0.098 ± 0.0013      | 0.076 ± 0.0016 #    | 0.032 ± 0.0012      | 0.025 ± 0.0020 #    |
| n = 12        | n = 5               | n = 14              | n = 3               |

TRPM7 and TRPM6—transient receptor potential melastatin type 7 and 6 channels, LA—left atrium, RA—right atrium, LV—left ventricle, RV—right ventricle, DV—extracellular divalent cations, DVF—extracellular divalent cation-free, n—number of cells, a.u.—arbitrary unit, and #—p < 0.001 for DV vs. DVF.

Figure 2. Comparison of the expression of TRPM6 and TRPM7 in left ventricular cardiomyocytes incubated for 2 h vs. 12 h in extracellular solutions with (A,B) and without (C,D) divalent cations (DV and DVF, respectively). (A,C) The cardiomyocytes were fixed after 2 h (filled columns) or 12 h (unfilled columns) of cell isolation: Alexa Fluor 488 for the TRPM7 and TRPM6 proteins (stained in green), Alexa Fluor 546 for the F-actin cytoskeleton (stained in red), and Hoechst 33342 for the nuclei (stained in blue). Scale bars indicate 20 μm. (B,D) Quantification of the intensity of the fluorescence expressed in arbitrary units (a.u.) # p < 0.001 expression after 12 h vs. 2 h of cardiomyocyte incubation.

2.2. Impact of Mg²⁺-Sensitive Currents on the Action Potential

To examine the role of Mg²⁺-sensitive currents on the electrical activity of cardiac myocytes, we recorded the total currents using a whole-cell voltage clamp, as well as the resting and action potentials using the current clamp. The cells were internally dialyzed and extracellularly perfused with solutions known to activate or inhibit the currents. The cells were internally dialyzed with either physiological levels of free intracellular [Mg²⁺] ([Mg²⁺]₀ = 0.8 mM) or with the Mg²⁺-free solution ([Mg²⁺]₀ ≈ 0 mM). The latter condition is known to cause a progressive activation of Mg²⁺-sensitive channels with time by removing the inhibition exerted by intracellular Mg²⁺ [15]. The cells were also extracellularly perfused with either physiological levels of [Mg²⁺] ([Mg²⁺]₀ = 0.9 mM) or with high Mg²⁺ ([Mg²⁺]₀ = 7.2 mM). High [Mg²⁺]₀ is known to cause a complete suppression of any activated Mg²⁺-sensitive current [15].
Figure 3 shows the whole-cell currents and action potentials measured in the cells dialyzed with either 0.8-mM [Mg\textsuperscript{2+}]_i (Figure 3A,C,E) or with 0-mM [Mg\textsuperscript{2+}]_i (Figure 3B,D,F). In these two groups of cells, there was no difference in the resting membrane potentials, which were also not changed by raising [Mg\textsuperscript{2+}]_o from 0.9 mM to 7.2 mM (for 0.8 mM [Mg\textsuperscript{2+}]_i, the resting membrane potential: −79.9 ± 2.6 mV in the control vs. −81.0 ± 2.1 mV in high [Mg\textsuperscript{2+}]_o; for 0 mM [Mg\textsuperscript{2+}]_i: −78.4 ± 2.8 mV in the control vs. −77.4 ± 3.7 mV in high [Mg\textsuperscript{2+}]_o, p = 0.308, ANOVA; n = 10).

Figure 3. Effect of Mg\textsuperscript{2+}-sensitive current activation on the action potential. (A,B) Whole-cell currents obtained by voltage ramps in cells dialyzed with 0.8-mM [Mg\textsuperscript{2+}]_i (A) or 0-mM [Mg\textsuperscript{2+}]_i (B) and superfused with extracellular solutions containing 0.9-mM [Mg\textsuperscript{2+}]_o or 7.2-mM [Mg\textsuperscript{2+}]_o. Insets: the [Mg\textsuperscript{2+}]_o-sensitive currents calculated as the differences between currents in the presence of 0.9-mM [Mg\textsuperscript{2+}]_o and those in 7.2-mM [Mg\textsuperscript{2+}]_o. Notice the outward-rectifying [Mg\textsuperscript{2+}]_o-sensitive current in the cell dialyzed with 0-mM [Mg\textsuperscript{2+}]_i. (C–F) The action potentials in the same cells as above, and the summary data of the action potential durations (APD) from all the cells dialyzed with 0.8-mM [Mg\textsuperscript{2+}] (C,E) or 0-mM [Mg\textsuperscript{2+}] (D,F) and the effect of raising the [Mg\textsuperscript{2+}]_o from 0.9 mM (black) to 7.2 mM (red). The APD was measured at 30%, 50%, and 90% repolarization (APD\textsubscript{30}, APD\textsubscript{50}, and APD\textsubscript{90}, respectively). Notice the lengthening of the APD by high [Mg\textsuperscript{2+}]_o in the cells dialyzed with low intracellular [Mg\textsuperscript{2+}]. Pacing frequency: 1 Hz. * p < 0.05 for 7.2-mM vs. 0.9-mM [Mg\textsuperscript{2+}]_o. n = 9 for the cells dialyzed with 0.8-mM [Mg\textsuperscript{2+}]_i; n = 10 for the cells dialyzed with 0-mM [Mg\textsuperscript{2+}]_i.
Figure 3A,B illustrates the membrane currents recorded under a voltage clamp during a descending ramp, following a preceding depolarizing ramp meant to inactivate the voltage-dependent Na\(^+\)- and Ca\(^{2+}\) currents (see Methods). The experiments were performed at 36 °C using K\(^+\)-containing intra- and extracellular solutions. In cells dialyzed with physiological levels of [Mg\(^{2+}\)]\(_o\) (0.8 mM; Figure 3A), the current–voltage relationship was characterized by a large inward current, consistent with the presence of the inward rectifier K\(^+\) current (I\(_{K1}\)) at potentials negative to −75 mV, and the current–voltage relationship was relatively flat at more positive potentials. Raising [Mg\(^{2+}\)]\(_o\) to 7.2 mM did not affect the current–voltage relationship, indicating that the high [Mg\(^{2+}\)]\(_o\) did not affect the I\(_{K1}\); and that no other Mg\(^{2+}\)-sensitive current was present (Figure 3A, inset). In the cells dialyzed with Mg\(^{2+}\)-free solution (0 mM [Mg\(^{2+}\)]\(_o\); Figure 3B), the current–voltage relationship was characterized by the presence of the inward rectifying current at physiological levels of [Mg\(^{2+}\)]\(_o\) to 7.2 mM, indicating the presence of a Mg\(^{2+}\)-sensitive current. This [Mg\(^{2+}\)]\(_o\)-sensitive current, calculated as the difference in the current–voltage relationships between the two conditions with different [Mg\(^{2+}\)]\(_o\), displays outward-rectifying properties similar to those of the TRPM6 and TRPM7 currents (Figure 3B, inset).

After recording membrane currents under a voltage clamp, we switched to the current clamp mode to record the action potentials in the same cells. Pig cardiomyocytes offer an experimental advantage when studying factors that affect the action potential, since channels carrying the transient outward K\(^+\) current (I\(_{O1}\)) are not expressed in this species [25,26]. The experiments were performed at 36 °C using K\(^+\)-containing intra- and extracellular solutions. In cells dialyzed with physiological levels of [Mg\(^{2+}\)]\(_o\) (0.8 mM; Figure 3A), the current–voltage relationship was characterized by a large inward current, consistent with the presence of the inward rectifier K\(^+\) current (I\(_{K1}\)) at potentials negative to −75 mV, and the current–voltage relationship was relatively flat at more positive potentials. Raising [Mg\(^{2+}\)]\(_o\) to 7.2 mM did not affect the current–voltage relationship, indicating that the high [Mg\(^{2+}\)]\(_o\) did not affect the I\(_{K1}\); and that no other Mg\(^{2+}\)-sensitive current was present (Figure 3A, inset). In the cells dialyzed with Mg\(^{2+}\)-free solution (0 mM [Mg\(^{2+}\)]\(_o\); Figure 3B), the current–voltage relationship was characterized by the presence of the inward rectifier K\(^+\) current at physiological levels of [Mg\(^{2+}\)]\(_o\) to 7.2 mM, indicating the presence of a Mg\(^{2+}\)-sensitive current. This [Mg\(^{2+}\)]\(_o\)-sensitive current, calculated as the difference in the current–voltage relationships between the two conditions with different [Mg\(^{2+}\)]\(_o\), displays outward-rectifying properties similar to those of the TRPM6 and TRPM7 currents (Figure 3B, inset).

2.3. Effects of High Extracellular [Mg\(^{2+}\)] on I\(_{Ca-L}\) and I\(_{K}\)

Considering that the changes in the action potential produced by high [Mg\(^{2+}\)]\(_o\) mainly affected the plateau and repolarization phases, we also examined the effect of [Mg\(^{2+}\)]\(_o\) on other currents that play a role during these phases, such as the L-type Ca\(^{2+}\) current (I\(_{Ca-L}\)) and the delayed rectifier K\(^+\) current (I\(_{K}\)). The analysis was done in cells dialyzed with 0.8-mM [Mg\(^{2+}\)]\(_o\) to inhibit the Mg\(^{2+}\)-sensitive currents. For the measurements of I\(_{K}\), K\(^+\)-containing intracellular and extracellular solutions were used, and nifedipine (25 µM) was included in the external solution, whereas, for the measurements of I\(_{Ca-L}\), Ca\(^{2+}\) was replaced by Cs\(^+\) in the external and pipette solutions, and 10-mM BAPTA was used in the pipette solution instead of EGTA. Figure 4A shows the bidirectional effect of the [Mg\(^{2+}\)]\(_o\) alteration on I\(_{Ca-L}\). Where lowering the [Mg\(^{2+}\)]\(_o\) by 10-fold to 0.09 mM reversibly increased the amplitude of I\(_{Ca-L}\) continuously monitored at 0 mV (I\(_{Ca-L}\), measured at the peak levels: from −5.4 ± 0.43 pA/pF to −6.5 ± 0.41 pA/pF; p < 0.05, paired t-test; n = 8; Figure 4B), raising the [Mg\(^{2+}\)]\(_o\) to 7.2 mM reversibly decreased the amplitude of I\(_{Ca-L}\) (peak I\(_{Ca-L}\); from −4.8 ± 0.39 pA/pF to −2.2 ± 0.17 pA/pF; p < 0.001, paired t-test; n = 13; Figure 4B; see reference [27]). As expected, the I\(_{K}\) blockers E4031 and HMR1556 had no effect on the I\(_{Ca-L}\) (Figure 4A). When wanting to test the consequence of an eventual modulation of the I\(_{Ca-L}\) by extracellular Mg\(^{2+}\), we kept E4031 constantly from the beginning of the experiment. The
I<sub>Ca-L</sub>–voltage relationships (see Figure 4A, inset) indicate that the [Mg<sup>2+</sup>]<sub>o</sub> changes shifted the activation curve of I<sub>Ca-L</sub> (to more negative potentials upon lowering the [Mg<sup>2+</sup>]<sub>o</sub> and to more positive potentials upon raising [Mg<sup>2+</sup>]<sub>o</sub>; see reference [27]).

Figure 5 shows that raising [Mg<sup>2+</sup>]<sub>o</sub> also decreased the magnitude of the total I<sub>K</sub> (Figure 5A at +30 mV to +50 mV p < 0.05 for 7.2-mM [Mg<sup>2+</sup>]<sub>o</sub> vs. the control, paired t-test; n = 4) and only mildly shifted the activation curve to the right (voltage at the half-maximal current V<sub>0.5</sub>: from ≈ −6 mV to ≈ −2 mV; n = 4; Figure 5B).

Since high [Mg<sup>2+</sup>]<sub>o</sub> did not change the APD in cells dialyzed with 0.8-mM [Mg<sup>2+</sup>]<sub>o</sub> (see Figure 3C,E), it is possible that there are two opposing and counterbalancing effects of high [Mg<sup>2+</sup>]<sub>o</sub> on the I<sub>Ca-L</sub> and I<sub>K</sub>. To test for this possibility, we applied high [Mg<sup>2+</sup>]<sub>o</sub> on cells in which the I<sub>K</sub> was partly blocked to offset such a balance. We initially performed preliminary tests to determine the optimum concentrations of the I<sub>K</sub> inhibitors (i.e., HMR1556 for the slow I<sub>K</sub> component I<sub>Ks</sub> and E 4031 for the rapid component I<sub>Kr</sub>) effective in producing a
partial block of $I_K$ without excessively prolonging the APD (not illustrated). Figure 6A shows the typical changes in action potentials in a perforated cell, whereas the summary data from four cell are presented in Figure 6B. Under the control conditions with 0.9-mM [Mg$^{2+}$]$_o$, the addition of small concentrations of $I_K$ inhibitors (100-nM HMR1556 and 500-nM E4031) lengthened the APD, as expected from a decrease of the repolarizing $K^+$ current (at a pacing rate of 1 Hz, APD$_{30}$: from 134.6 ± 28.5 ms to 177.8 ± 19.9 ms, APD$_{50}$: from 192.9 ± 20.9 ms to 267.4 ± 24.1 ms, and APD$_{90}$: from 242.4 ± 17.5 ms to 358.0 ± 18.3 ms; * $p < 0.05$, except for the APD$_{30}$, for which $p > 0.05$, paired t-test; $n = 4$). Consistent with a decreased relative contribution of $I_K$, raising the [Mg$^{2+}$]$_o$ to 7.2 mM in the presence of the $I_K$ blockers decreased the APD (to 163.9 ± 20.9 ms, to 246.0 ± 21.1 ms, and to 323.5 ± 15.5 ms for APD$_{30}$, APD$_{50}$, and APD$_{90}$, respectively), indicating a predominant effect of $I_{Ca-L}$ suppression by high [Mg$^{2+}$]$_o$ under these conditions. Qualitatively similar results were obtained in three other cells dialyzed with 0.8-mM [Mg$^{2+}$]$_i$ under the ruptured cell membrane conditions (not illustrated). These results suggest that the lack of effect of raising [Mg$^{2+}$]$_o$ on the APD in cells dialyzed with 0.8-mM [Mg$^{2+}$]$_i$ reflects a balance in the effects of the decreases of both $I_{Ca-L}$ and $I_K$ on repolarization.

![Figure 6. Effect of a partial $I_K$ block and high [Mg$^{2+}$]$_o$ on the action potential. (A) APs recorded at 36 °C using $K^+$-containing intra- and extracellular solutions under perforated patch conditions and initially superfused with control extracellular solutions containing 0.9-mM [Mg$^{2+}$]. A combination of HMR1556 (100 nM) and E4031 (500 nM) was then added in 0.9-mM [Mg$^{2+}$]$_o$ before applying 7.2-mM [Mg$^{2+}$]$_o$, together with the drugs. (B) Summary data of the AP duration (APD) at 30%, 50%, and 90% repolarization (APD$_{30}$, APD$_{50}$, and APD$_{90}$, respectively) measured under the control conditions (unshaded column) in the presence of the $I_K$ inhibitors (grey column) and in the presence of the $I_K$ inhibitors but with the [Mg$^{2+}$]$_o$ raised to 7.2 mM (red column). * $p < 0.05$ for the presence vs. absence of the $I_K$ inhibitors (in 0.9-mM [Mg$^{2+}$]$_o$). # $p < 0.05$ for 7.2-mM vs 0.9-mM [Mg$^{2+}$]$_o$ in the presence of the $I_K$ inhibitors (n = 4). Notice the shortening of the APD$_{50}$ and APD$_{90}$ by high [Mg$^{2+}$]$_o$ in the presence of the $I_K$ blockers.

3. Discussion

The results from the present study suggest the presence of TRPM6 and TRPM7 proteins in cardiac myocytes, given that immunofluorescent activity was detected in cells treated with the anti-TRPM6 or anti-TRPM7 antibody, but in contrast, no such activity was detected in the negative controls. Furthermore, the results showed that the cardiac myocyte action potential duration (APD) was shortened in the presence of a current likely due TRPM6 or TRPM7 in that it was activated by dialysis with low [Mg$^{2+}$]$_o$, was absent in cells dialyzed with 0.8-mM [Mg$^{2+}$]$_i$, and was suppressed by high [Mg$^{2+}$]$_o$. Thus, the results are consistent with our previous proposal that the Mg$^{2+}$-sensitive channels in the heart are likely due to TRPM6 and/or TRPM7 proteins [15] and with a possible role of the cardiac Mg$^{2+}$-sensitive channels in modulating the electrical activity.
3.1. Molecular Candidate for Mg$^{2+}$-Sensitive Channels

Many TRP proteins form nonselective cation channels and are, therefore, the molecular candidates for similar native channels [28]. In determining the involvement of TRPs expressed in the heart, the inhibition by Mg$^{2+}$ is a key distinguishing feature. For the TRPC4/C5 channels, Mg$^{2+}$ causes a voltage-dependent partial block of the outward currents and results in a doubly rectifying current–voltage relationship [29,30]. Such a Mg$^{2+}$ effect on the TRPC4/C5 channels is different from the voltage-independent slow inhibition seen in the Mg$^{2+}$-sensitive channels [15,31]. Rather, the Mg$^{2+}$ inhibition and the biophysical characteristics of the cardiac channels [15] resemble those of the TRPM6 and TRPM7 channels [16,19]. Our detection of TRPM6 and TRPM7 proteins by immunofluorescence suggests that the channels are expressed in both the atrial and ventricular chambers. It appears that the TRPM6 and TRPM7 channel proteins were present in both the surface membrane and intracellularly. However, where exactly the proteins are located intracellularly could not be determined in the present study. Nonetheless, a novelty of the present findings is that TRPM6 was immunodetected in pig myocytes (but see Limitations of our Study below), whereas TRPM6 expression has been reported to be lacking in other studies of cardiac tissues [32]. As such, the present results suggest that TRPM6 and TRPM7 proteins are the most likely constituents of the Mg$^{2+}$-sensitive cardiac channels.

There are, however, slight differences in the divalent cation permeability profiles between the cardiac Mg$^{2+}$-sensitive channels [15] and overexpressed TRPM7 channels [16]. It is possible that, even though the core structure of the channel may be the same, different channel subunits or regulatory units may occur in the native cells. Furthermore, the TRPM7 channel activity has been shown to be altered by heteromultimeric interactions with TRPM6 [33]. Nevertheless, in order to ascertain the cardiac channel identity, further studies are still required to correlate the activity of the TRPM6 and TRPM7 proteins detected in myocytes with the Mg$^{2+}$-sensitive current.

3.2. Modulation of Cardiac Electrical Activity

The possible contribution of the Mg$^{2+}$-sensitive current to cardiac electrical activity is unknown. Like in other cells, nonselective cation channels contribute to the resting membrane potential in the heart [34]. These may include Mg$^{2+}$-sensitive channels. Given the small Mg$^{2+}$-sensitive inward current and the large $I_{K1}$ at a negative potential in the heart, the Mg$^{2+}$-sensitive channels would not be expected to contribute significantly to the background non-K$^+$ permeability in resting cardiomyocytes. This is consistent with our findings here, showing no effect of raising the extracellular Mg$^{2+}$ concentration on the resting membrane potential. However, in other tissues such as vascular smooth muscle, the contribution of nonselective cation channels, some of which resemble TRPM6 and TRPM7, could be more important [35,36].

Cation nonselective channels may also contribute to shaping the cardiac action potential. In atrial cells, a stretch-activated cation nonselective channel has been shown to contribute to both the resting and action potentials [37]. Since the net ion current is small during the plateau phase of the action potential, changes in the large monovalent cation effluxes through Mg$^{2+}$-sensitive channels at positive potentials may have significant effects on the action potential. Consistent with such an expectation, our present results showed that the activation of the cardiac Mg$^{2+}$-sensitive channels shortened the APD. It is unlikely that the APD shortening is due to a larger outward $I_{K1}$ following the removal of the Mg$^{2+}$ block in low [Mg$^{2+}$] conditions, since endogenous polyamines would still continue to provide a sufficient block of the outward $I_{K1}$ and since high Mg$^{2+}$ suppressed the outward current while having no effect on the inward currents. Our results suggest that there is practically no contribution of TRPM6 and TRPM7 currents to the AP when [Mg$^{2+}$], is at the physiological levels. This result is consistent with a lack of changed currents through mutant TRPM7 channels expressed in cultured cardiomyocytes on the action potentials measured in such cells [39].
3.3. Clinical Implications

A key question concerns the conditions under which the Mg$^{2+}$-sensitive channels may contribute to cardiac electrical activity. Under the physiological conditions (free [Mg$^{2+}$], 0.8 mM; IC$_{50}$ ≈ 0.25 mM; [15,31]), the channels are expected to be substantially inhibited by Mg$^{2+}$. However, the Mg$^{2+}$-sensitive current may contribute to APD if the sensitivity to [Mg$^{2+}$] is decreased by regulatory processes or channel mutations or if [Mg$^{2+}$], is decreased to low levels by disease conditions such as chronic hypomagnesaemia. Indeed, the TRPM7 and related native channels show constitutive activity, some of it in cells where the intracellular ion composition (including [Mg$^{2+}$]) remains relatively unperturbed [16,18,40], suggesting the presence of other regulatory processes. In cardiac cells, besides [Mg$^{2+}$], the Mg$^{2+}$-sensitive channels are also regulated by factors such as the pH change and membrane phospholipid metabolism [14,15,41], but it is still not known whether such regulatory processes can induce the constitutive activity of the channels. In the present study, we show that the expression of the TRPM6 and TRPM7 channels is modulated by incubation in divalent cation-free extracellular conditions. Thus, the contributions of the Mg$^{2+}$-sensitive current to the AP may vary depending on the status of the extracellular divalent cation homeostasis.

Earlier studies demonstrated TRPM7 activation by free oxygen radicals during prolonged neuronal ischemia [42]. To date, the functional role of TRPM7 and especially that of TRPM6 are less clearly understood in heart cardiomyocytes compared to vascular smooth muscle cells [43], neurons, or other cell types [44,45]. The molecular and electrophysiological characterizations of TRPM7 in the heart have focused predominantly on cardiac fibroblasts. TRPM7 activation in human atrial fibroblasts leads to fibrogenesis and atrial fibrillation [46]. Additionally, the variability of the TRPM7 current density in human right atrial cardiomyocytes is related to the clinical history, being higher in disease conditions such as atrial fibrillation [47,48] and in ischemic heart disease [48]. Very recently, we also demonstrated the presence and co-expression of both TRPM6 and TRPM7 in cardiomyocytes from the four chamber walls of the human heart [22] and also showed that ischemic heart disease may increase their expression, suggesting that chanzymes are involved in the pathophysiology of the disease.

3.4. Limitations of the Study

Given the current uncertainty about the detection of TRPM6 in cardiac cells, it is important to examine how convincing the evidence is for the presence of TRPM6 in our study.

The present study relied on immunostaining to detect the presence of TRPM7 and TRPM6. Previous studies have demonstrated limitations of antibody staining methods to determine the expression of TRP channels (e.g., see [49]). The specificity of the commercial antibodies used in our study was not directly tested, e.g., using blocking peptides or using cells lines in which the TRPM7 and TRPM6 genes were knocked out, silenced or overexpressed.

Our results, using swine cardiomyocytes, are in concordance to human TRPM6 and TRPM7 immunodetected fluorescence distribution, which also suggested both ion channel expression in the walls of all cardiac chambers [22]. In that study RT-PCR confirmed the presence of mRNA for both TRPM7 and TRPM6, hence supporting the immunostaining data, but the interpretation of RT-PCR also has limitations due to possible contamination by non-cardiomyocyte cells. We used on pig myocytes the same antibodies as in that study. Although these antibodies are recognized to work on human proteins, a key limitation of the present study is that there is no previous evidence of their specificity in pig cells and there are no readily available pig-specific TRPM6 antibodies in the market. Given that there is a great amount of antibody recognition between human- and pig epitopes in cardiac tissue [50], we used the same TRPM6 antibody (designed for human, mouse, and rat), which being polyclonal, would also be able to bind to epitopes in other species.
Although TRPM6 was detected in pig cardiomyocytes but not in negative controls, the specificity of the antibody in pig still requires verification in future studies.

An important limitation of the electrophysiological study is that there are, as yet, no known specific pharmacological blockers available for Mg\textsuperscript{2+}-sensitive- and related channels. Presently, we used the block by Mg\textsubscript{2+}o as an extracellular tool to isolate the Mg\textsuperscript{2+}-sensitive current. There was therefore a possible confounding issue in that Mg\textsubscript{2+}o could also suppress \(I_{\text{Ca-L}}\) and \(I_{\text{K}}\). In other studies, the Mg\textsubscript{2+}o effect on \(I_{\text{K}}\) was more prominent on tail currents during depolarization [51], and increasing Mg\textsubscript{2+}o caused either a lengthening or a shortening of APD, depending on the level of Mg\textsubscript{2+}o [52]. However, in the present study, the Mg\textsubscript{2+}o effects on action potentials that were due to \(I_{\text{Ca-L}}\) and \(I_{\text{K}}\) seemed to balance each other out sufficiently for their effects to be isolated from those on the Mg\textsuperscript{2+}-sensitive current.

3.5. Conclusion

In conclusion, our results show the presence of TRPM7 and, to a certain extent, suggest that of TRPM6 proteins in pig cardiomyocytes, making these proteins the molecular candidates for cardiac Mg\textsuperscript{2+}-sensitive channels. The activation of the Mg\textsuperscript{2+}-sensitive channels shortened the cardiomyocyte APD. Although the pathophysiological conditions in which the channels are activated remain unclear, the effect of the Mg\textsuperscript{2+}-sensitive current on the APD may be important in understanding the therapeutic processes in which Mg\textsuperscript{2+} is empirically used to treat arrhythmias, as well as in linking the changes in Mg\textsuperscript{2+} homeostasis to other cardiac disease conditions.

4. Materials and Methods

We used isolated, single cardiomyocytes of a pig heart. This study was carried out in compliance with the Guide for the Care and Use of Laboratory Animals (NIH). All experiments were performed according to the European Community guiding principles and approved by the State Food and Veterinary Service of the Republic of Lithuania (No. G2-68, 21 June 2017) and by the Belgian laboratory license No. LA-1210253.

4.1. Cell Isolation

The methods used for the dissociation of pig cells have been described before [15,25]. In short, for electrophysiology studies, a piece of the left ventricular wall was excised, and its supplying artery was cannulated and perfused at 37 °C and at constant pressure for 30 min with an oxygenated Ca\textsuperscript{2+}-free Tyrode solution, followed by a 20- to 25-min perfusion with a Ca\textsuperscript{2+}-free Tyrode solution containing 0.1-mg mL\textsuperscript{-1} protease (type XIV, Sigma-Aldrich, St. Louis, MO, USA) and 1.4-mg mL\textsuperscript{-1} collagenase (type A, Boehringer-Mannheim, Mannheim, Germany). After a 15-min washing perfusion with a 0.18-mM Ca\textsuperscript{2+} Tyrode solution, the tissue was removed from the perfusion and was cut into small pieces. The cells were dispersed by gentle mechanical agitation. [Ca\textsuperscript{2+}]\textsubscript{o} was raised in a stepwise manner, and the cells were stored at room temperature (21–22 °C). Ca\textsuperscript{2+}-tolerant rod-shaped ventricular myocytes with clear striations were selected for the electrophysiological studies.

For the immunofluorescence studies, the cardiomyocytes were isolated from a small tissue specimen as previously described [53]. In short, each tissue specimen (LA, RA, LV, and RV) was fine-cut in an oxygenated nominally Ca\textsuperscript{2+}-free Tyrode solution (see the composition below) supplemented with 3-mg/mL 2,3-butanedione monoxime, which was washed out 2 to 3 times before the enzyme application. The cardiac tissue chunks were transferred to a beaker with nominally Ca\textsuperscript{2+}-free Tyrode solution supplemented with 1-mg/mL bovine serum albumin (BSA), 1-mg/mL collagenase (215 U/mg, type 2; Worthington Biochemical Corporation, Lakewood, NJ, USA), and 0.5-mg/mL protease (7–14 U/mg, type XXIV; Sigma-Aldrich, St. Louis, MO, USA) and continuously bubbled with 100% O\textsubscript{2}. After 30 min of shaking in a water bath at 37 °C, the solution with both enzymes was replaced by fresh solution containing only collagenase (1 mg/mL) and shaken until cardiomyocytes appeared in the aliquots obtained from the mixture.
the yield appeared to be optimal, the leftovers of the tissue chunks were resuspended in nominally Ca\(^{2+}\)-free Tyrode and gently subjected to trituration by suction with a pipette. The cell suspension was filtered, centrifuged, and washed 2 to 3 times either with normal (divalent cation-containing) or with divalent cation-free Tyrode solution and stored at room temperature.

4.2. Electrophysiology

Whole-cell currents were recorded under a voltage clamp, and the action potentials were recorded under a current clamp at 36 °C within 4 h after cell isolation. The membrane currents of interest were measured using 2-s descending voltage ramps from +80 mV to −120 mV applied every 10 s after a 600-ms pre-step at 0 mV from a holding potential of −80 mV, designed to inactivate the voltage-dependent Na\(^+\) and L-type Ca\(^{2+}\) currents. For measuring the L-type Ca\(^{2+}\) currents (I\(_{\text{Ca-L}}\)), 400-ms depolarizations to various potentials were given after a 400-ms pre-step at −40 mV, designed to inactivate the voltage-dependent Na\(^+\) current. The total delayed rectifier K\(^+\) currents I\(_{\text{K}}\) were measured using voltage steps from a holding potential of −40 mV to various positive potentials, and the tail currents were then measured upon reverting to −50 mV. The action potentials were measured by stimulating with a 2-ms rectangular pulse at a frequency of 1 Hz. The action potential duration (APD) was measured at 30% (APD\(_{30}\)), 50% (APD\(_{50}\)), and 90% (APD\(_{90}\)) repolarization. The current and voltage protocols were generated and data recorded online using the Axopatch 200B amplifier and pClamp 8.1 software via the Digidata 1322A acquisition system (Axon instruments, Union City, CA, USA).

4.3. Immunofluorescence

Enzymatically dissociated cardiomyocytes were allowed to settle on the bottom of 8-chamber slides. The cells were permeabilized and incubated with primary rabbit polyclonal anti-TRPM7 (#ACC-047; Alomone Labs, Jerusalem, Israel) or rabbit polyclonal anti-TRPM6 antibody (#ACC-046; Alomone Labs, Jerusalem, Israel) diluted (1:200) in PBS containing 3% BSA in blocking buffer overnight at 4 °C. The TRPM6 and TRPM7 antibodies were obtained from the same company in order to minimize the possibility of cross-reactivity during immunolabeling. For the negative controls, incubation with the primary antibody was omitted to check for nonspecific binding of the secondary antibody. The cells were incubated for 1 h with a fluorescently labeled secondary antibody (donkey anti-rabbit IgG; Alexa Fluor\(^{®}\) 488 conjugate; A21206, Invitrogen, Thermo Fisher Scientific, Rockford, IL, USA; dilution 1:200) co-stained (for 20 min) with Phalloidin-Alexa Fluor\(^{®}\) 546 (A22283, Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA; dilution 1:100) and with Hoechst 33342 (B2261, Sigma-Aldrich, St. Louis, MO, USA; for 10 min) for labeling of the F-actin cytoskeleton and of the nucleus, respectively. Cardiomyocytes were visualized under a confocal laser scanning microscope (Olympus BX61, Olympus Corporation, Tokyo, Japan) from which images were taken using the same scanning parameters for both the TRPM7 and TRPM6 proteins in all the cardiomyocyte preparations.

4.4. Solutions and Drugs

The standard Tyrode solution used during cell dissociation contained (in mM): 135 NaCl, 5.4 KCl, 0.9 MgCl\(_2\), 1.8 CaCl\(_2\), 0.33 NaH\(_2\)PO\(_4\), 10 HEPES, and 10 glucose; the pH was adjusted to 7.4 with NaOH. During the patch clamp measurements, the cells were superfused with a solution of similar composition, except that, when necessary, K\(^+\) was replaced by Cs\(^+\), and the Mg\(^{2+}\) levels were changed. The standard pipette solution was contained (in mM): 155 KCl, 5.5 MgCl\(_2\), 5 Na\(_2\)ATP, 1 EGTA, 0.1 Na\(_2\)GTP, and 5 HEPES (pH 7.25; adjusted with KOH) and was modified by changing the levels of Mg\(^{2+}\), by replacing K\(^+\) with Cs\(^+\), or by substituting EGTA with BAPTA. The phosphate-buffered saline (PBS) used in immunofluorescence contained (in mM): 155.2 NaCl, 2.71 Na\(_2\)HPO\(_4\), 2H\(_2\)O, and 1.54 KH\(_2\)PO\(_4\) (pH 7.4; adjusted with NaOH).
HMR1556 was from Aventis Pharma, Frankfurt Am Main, Germany, and E-4031 was from Tocris, Bristol, UK. All the other drugs or chemicals were from Sigma-Aldrich (Bornem, Belgium) or Merck (Darmstadt, Germany). Nifedipine was prepared as a stock solution in ethanol and was protected from light, whereas HMR1556 was prepared in dimethyl sulfoxide (DMSO). All the other chemicals were dissolved in water.

4.5. Data and Statistical Analyses

An electrophysiology data analysis was performed using Clampfit 8.2 (Axon Instruments, Union City, CA, USA) and Origin 7 (Microcal, Northampton, MA, USA).

The distribution of the immunofluorescence was analyzed using the Olympus Fluoview FV1000 (Olympus Corporation, Tokyo, Japan) and ImageJ software. Sixty-times magnifying (60×) of the oil immersion objectives were utilized for all the acquisitions. The images were presented as stacks of 8–10 slices at a fixed intensity. The cardiomyocyte area (pixels) and fluorescence intensity were measured in stacks using Imaris software (Bitplane AG, Zurich, Switzerland). The immunodetected TRPM6 and TRPM7 protein levels were calculated by the formula: fluorescence intensity × 1000/cell area. In order to reduce the effect on any statistical confounder, the same parameters for fluorescence intensity detection (image acquisition control and spectral settings, etc.) were always applied. In addition, the immunofluorescence reading was blinded, as the conditions used to keep the cells were unknown to the person performing the reading.

The average data were presented as the mean ± standard error of the mean (S.E.M) or box plots, with n indicating the number of cells studied under each condition. The means were compared using the two-tailed Student’s t-test, whereas differences among the multiple groups were evaluated using an analysis of variance (ANOVA). p ≤ 0.05 was taken as the threshold for statistical significance.

Author Contributions: Conceptualization, A.G., K.M., and R.M.; investigation, A.G., I.A., B.M.I., F.E., and R.M.; formal analysis, A.G., I.A., B.M.I., F.E., and R.M.; validation, A.G., K.M., and R.M.; and writing—review and editing A.G., K.M., and R.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by FWO (the Flemish Foundation for Science) Grant G.0634.07. AG was supported by the Belgian Technical Cooperation. RM was supported by the Research Council of the KULeuven Grant SF/08/021 and by the Research Council of Lithuania (LMTLT, Agreement No. VP1-3.1-ŠMM-08-K-01-022). The APC was funded by a VLIR-UOS grant to KM in the frame of an Institutional University Cooperation between Flemish universities and the Université Catholique de Bukavu.

Institutional Review Board Statement: All experiments were performed according to the European Community guiding principles and approved by the State Food and Veterinary Service of the Republic of Lithuania (No. G2-68, 21 June 2017) and by the Belgian laboratory license No. LA-1210253.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. DiFrancesco, D. Serious workings of the funny current. Prog. Biophys. Mol. Biol. 2006, 90, 13–25. [CrossRef]
2. Falcón, D.; Gáleo-Otero, I.; Calderón-Sánchez, E.; Del Toro, R.; Martin-Bornez, M.; Rosado, J.A.; Hmadcha, A.; Smani, T. TRP channels: Current perspectives in the adverse cardiac remodeling. Front. Physiol. 2019, 10, 159. [CrossRef] [PubMed]
3. Hof, T.; Chaigne, S.; Récalde, A.; Salli, L.; Brette, F.; Guinamard, R. Transient receptor potential channels in cardiac health and disease. Nat. Rev. Cardiol. 2019, 16, 344–360. [CrossRef] [PubMed]
4. Hu, Y.; Li, Q.; Kurahara, L.H.; Shioi, N.; Hiraiishi, K.; Fujita, T.; Zhu, X.; Inoue, R. An Arrhythmic Mutation E7K Facilitates TRPM4 Channel Activation via Enhanced PIP2 Interaction. Cells 2021, 10, 983. [CrossRef]
5. Feng, J.; Zong, P.; Yan, J.; Yue, Z.; Li, X.; Smith, C.; Ai, X.; Yue, L. Upregulation of transient receptor potential melastatin 4 (TRPM4) in ventricular fibroblasts from heart failure patients. Pflügers Arch. 2021, 473, 521–531. [CrossRef] [PubMed]
6. Seth, M.; Zhang, Z.S.; Mao, L.; Graham, V.; Burch, J.; Stiber, J.; Tsiokas, L.; Winn, M.; Abramowitz, J.; Rockman, H.A.; et al. TRPC1 channels are critical for hypertrophic signaling in the heart. Circ. Res. 2009, 105, 1023–1030. [CrossRef]
7. Alvarez, J.; Coulombe, A.; Cazorla, O.; Ugur, M.; Rauzier, J.M.; Magyar, J.; Mathieu, E.L.; Boulay, G.; Souto, R.; Bideaux, P.; et al. ATP/UTP activate cation-permeable channels with TRPC3/7 properties in rat cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2008, 295, H21–H28. [CrossRef] [PubMed]

8. Onohara, N.; Nishida, M.; Inoue, R.; Kobayashi, H.; Sumimoto, H.; Sato, Y.; Mori, Y.; Nagao, T.; Kurose, H. TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy. EMBO J. 2006, 25, 5305–5316. [CrossRef]

9. Chaigne, S.; Cardouat, G.; Louradour, J.; Vaillant, F.; Charron, S.; Sacher, F.; Ducret, T.; Guinamard, R.; Vignmond, E.; Hof, T. Transient receptor potential vanilloid 4 channel participates in mouse ventricular electrical activity. Am. J. Physiol. Heart Circ. Physiol. 2021, 320, H1156–H1169. [CrossRef]

10. Guinamard, R.; Chatelier, A.; Demion, M.; Potreau, D.; Patri, S.; Rahmati, M.; Bois, P. Functional characterization of a Ca²⁺-activated non-selective cation channel in human atrial cardiomyocytes. J. Physiol. 2004, 558, 75–83. [CrossRef]

11. Sah, R.; Mesirca, P.; Van den Boogert, M.; Rosen, J.; Mably, J.; Mangoni, M.E.; Clapham, D.E. Ion channel-kinase TRPM7 is required for maintaining cardiac automaticity. Proc. Natl. Acad. Sci. USA 2013, 110, E3037–E3046. [CrossRef] [PubMed]

12. Sah, R.; Mesirca, P.; Mason, X.; Gibson, W.; Bates-Withers, C.; Van den Boogert, M.; Chaudhuri, D.; Pu, W.T.; Mangoni, M.E.; Clapham, D.E. Timing of myocardial Trpm7 deletion during cardiogenesis variably disrupts adult ventricular function, conduction, and repolarization. Circulation 2013, 128, 101–114. [CrossRef] [PubMed]

13. Volk, T.; Schwoerer, A.P.; Thiessen, S.; Schultz, J.H.; Ehmke, H. A polycystin-2-like large conductance cation channel in rat left ventricular myocytes. Cardiovasc. Res. 2008, 75, 58–68. [CrossRef]

14. Gwanyanya, A.; Sipido, K.R.; Vereecke, J.; Mubagwa, K. ATP and PIP2 dependence of the magnesium-inhibited, TRPM7-like cation channel in cardiac myocytes. Am. J. Physiol. Cell Physiol. 2009, 296, C627–C635. [CrossRef]

15. Gwanyanya, A.; Amuzescu, B.; Zakharov, S.I.; Macianskiene, R.; Sipido, K.R.; Bolotina, V.M.; Vereecke, J.; Mubagwa, K. Magnesium-inhibited, TRPM6/7-like channel in cardiac myocytes: Permeation of divalent cations and pH-mediated regulation. J. Physiol. 2004, 559, 761–776. [CrossRef]

16. Monteilh-Zoller, M.K.; Hermosura, M.C.; Nadler, M.J.; Scharenberg, A.M.; Penner, R.; Fleig, A. TRPM7 provides an ion channel mechanism for cellular entry of trace metal ions. J. Gen. Physiol. 2003, 121, 49–60. [CrossRef]

17. Nadler, M.J.; Hermosura, M.C.; Inabe, K.; Perraud, A.L.; Zhu, Q.; Stokes, A.J.; Kurotski, T.; Kinet, J.P.; Penner, R.; Scharenberg, A.M.; et al. LTRPC7 is a Mg.ATP-regulated divalent cation channel required for cell viability. Nature 2001, 411, 590–595. [CrossRef]

18. Schmitz, C.; Perraud, A.L.; Johnson, C.O.; Inabe, K.; Smith, M.K.; Penner, R.; Kurotski, T.; Fleig, A.; Scharenberg, A.M. Regulation of vertebrate cellular Mg²⁺ homeostasis by TRPM7. Cell 2003, 114, 191–200. [CrossRef]

19. Voets, T.; Nilius, B.; Hoefs, S.; van der Kemp, A.W.; Droogmans, G.; Bindels, R.J.; Hoenderop, J.G. TRPM6 forms the Mg²⁺ influx channel involved in intestinal and renal Mg²⁺ absorption. J. Biol. Chem. 2004, 279, 19–25. [CrossRef]

20. Fleig, A.; Chubanov, V. TRPM7. Handb. Exp. Pharmacol. 2014, 222, 521–546. [PubMed]

21. Zhang, Y.J.; Ma, N.; Su, F.; Liu, H.; Mei, J. Increased TRPM6 expression in atrial fibrillation patients contribute to atrial fibrosis. Exp. Mol. Pathol. 2015, 98, 486–490. [CrossRef]

22. Andriulė, I.; Pangonytė, D.; Almanaiti, M.; Patamsytė, V.; Kuprtytė, M.; Karčiauskas, D.; Mubagwa, K.; Macianskiene, R. Evidence for the expression of TRPM6 and TRPM7 in cardiomyocytes from all four chamber walls of the human heart. Sci. Rep. 2021, 11, 1–14.

23. Tashiro, M.; Inoue, H.; Konishi, M. Physiological pathway of magnesium influx in rat ventricular myocytes. Biophys. J. 2014, 107, 2049–2058. [CrossRef]

24. Gräbner, W.; Fitzer, P. Number of nuclei in isolated myocardial cells of pigs. Virchows Arch. B Cell Pathol. 1974, 15, 279–294.

25. Macianskiene, R.; Moccia, F.; Sipido, K.R.; Flameng, W.; Mubagwa, K. Channels involved in transient currents unmasked by removal of extracellular calcium in cardiac cells. Am. J. Physiol. Heart Circ. Physiol. 2002, 282, H1879–H1888. [CrossRef] [PubMed]

26. Li, G.R.; Du, X.L.; Siow, Y.L.; O, K.; Tse, H.F.; Lau, C.P. Calcium-activated transient outward chloride current and phase 1 repolarization of swine ventricular action potential. Cardiovasc. Res. 2003, 58, 89–98. [CrossRef]

27. Hartzell, H.C.; White, R.E. Effects of magnesium on inactivation of the voltage-gated calcium current in cardiac myocytes. J. Gen. Physiol. 1989, 94, 745–767. [CrossRef]

28. Chpanov, D.E. TRP channels as cellular sensors. Nature 2003, 426, 517–524. [CrossRef] [PubMed]

29. Schlingmann, K.P.; Weber, S.; Peters, M.; Niemann-Nejsum, L.; Vitzthum, H.; Klingel, K.; Kratz, M.; Haddad, E.; Ristoff, E.; Dinour, D.; et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRP gene family. Nat. Genet. 2002, 31, 166–170. [CrossRef] [PubMed]
34. Isenberg, G. Nonselective cation channels in cardiac and smooth muscle cells. *Nonselective Cation Channels* 1993, 66, 247–260.

35. Zakharov, S.I.; Mongayt, D.A.; Cohen, R.A.; Bolotina, V.M. Monovalent cation and L-type Ca\(^{2+}\) channels participate in calcium paradox-like phenomenon in rabbit aortic smooth muscle cells. *J. Physiol.* 1999, 514, 71–81. [CrossRef] [PubMed]

36. Bae, Y.M.; Park, M.K.; Lee, S.H.; Ho, W.K.; Earm, Y.E. Contribution of Ca\(^{2+}\)-activated K\(^+\) channels and non-selective cation channels to membrane potential of pulmonary arterial smooth muscle cells of the rabbit. *J. Physiol.* 1999, 514, 747–758. [CrossRef]

37. Zhang, Y.H.; Youm, J.B.; Sung, H.K.; Lee, S.H.; Ryu, S.Y.; Ho, W.K.; Earm, Y.E. Stretch-activated and background non-selective cation channels in rat atrial myocytes. *J. Physiol.* 2000, 523, 607–619. [CrossRef] [PubMed]

38. Lopatin, A.N.; Makhina, E.N.; Nichols, C.G. Potassium channel block by cytoplasmic polyamines as the mechanism of intrinsic rectification. *Nature* 1994, 372, 366–369. [CrossRef]

39. Cartwright, J.H.; Aziz, Q.; Harmer, S.C.; Thayyil, S.; Tinker, A.; Munroe, P.B. Genetic variants in TRPM7 associated with unexplained stillbirth modify ion channel function. *Hum. Mol. Genet.* 2020, 29, 1797–1807. [CrossRef] [PubMed]

40. Kozak, J.A.; Kerschbaum, H.H.; Cahalan, M.D. Distinct properties of CRAC and MIC channels in RBL cells. *J. Gen. Physiol.* 2002, 120, 221–235. [CrossRef]

41. Macianskiene, R.; Gwanyanya, A.; Vereecke, J.; Mubagwa, K. Inhibition of the magnesium-sensitive TRPM7-like channel in cardiac myocytes by nonhydrolysable GTP analogs: Involvement of phosphoinositide metabolism. *PLoS ONE* 2017, 12, e0170923. [CrossRef]

42. Nilius, B.; Flockerzi, V. What do we really know and what do we need to know: Some controversies, perspectives, and surprises. *Handb. Exp. Pharmacol.* 2014, 223, 1239–1280.

43. Scalia, C.R.; Gendusa, R.; Basciu, M.; Riva, L.; Tusa, L.; Musarò, A.; Veronese, S.; Formenti, A.; D’Angelo, D.; Ronzio, A.G.; et al. Epitope recognition in the Human–Pig comparison model on fixed and embedded material. *J. Histochem. Cytochem.* 2015, 63, 805–822. [CrossRef]

44. Po, S.S.; Wang, D.W.; Johnson, J.P., Jr.; Nie, L.; Bennett, P.B. Modulation of HERG potassium channels by extracellular magnesium and quinidine. *J. Cardiovasc. Pharmacol.* 1999, 33, 181–185. [CrossRef] [PubMed]

45. Zhang, S.; Sawanobori, T.; Adaniya, H.; Hirano, Y.; Hiraoka, M. Dual effects of external magnesium on action potential duration in guinea pig ventricular myocytes. *Am. J. Physiol. Heart Circ. Physiol.* 1995, 268, H2321–H2328. [CrossRef] [PubMed]

46. Macianskiene, R.; Martisiene, I.; Zablockaite, D.; Gendviliene, V. Characterization of Mg\(^{2+}\)-regulated TRPM7-like current in human atrial myocytes. *J. Biomed. Sci.* 2012, 19, 75. [CrossRef] [PubMed]